Induction therapy with tumor necrosis factor-α (TNF-α) inhibitors is highly effective for the
treatment of Crohn's disease. However, there are primary nonresponders (PNR) of TNF-α …

Introduction Adalimumab is effective for maintenance of remission in patients with Crohn's
disease (CD) at a dose of 40 mg subcutaneously every 2 weeks. However, adalimumab is …

Background: Biosimilars have the potential to create competition, lower costs, and increase
patient access to biological medications. However, biological medications are sensitive to …

Background: efficacy and safety were evaluated after switching to a biosimilar infliximab
(CPT-13) in patients with inflammatory bowel disease (IBD). However, few cohort studies …

While biomedical investigation has greatly advanced, investigators have lost touch with and
inadvertently corrupted significant nomenclature at the foundation of their science …

Inflammatory bowel diseases (IBD) consist of Crohn's disease and ulcerative colitis. These
are conditions that, although managed by pediatric gastroenterologists, are encountered …

Immune-mediated inflammatory diseases share several pathogenic pathways and this
pushes sometimes to extrapolate from one disease or indication to others. A biosimilar can …

Background and study aims The infliximab biosimilar CT-P13 was the first biosimilar drug
targeting tumor necrosis factor-α. However, its efficacy and safety in real-world clinical …

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal
tract. The pathogenesis in not fully unraveled yet, but is summarized by an abnormal …

During COVID-19 infection, virus and host cell interactions lead to the acute production of
very strong immune mediators. The clinical status caused by damage throughout the body is …